News | March 17, 2022
Biological E gears up for new phase of vaccination drive
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Support from DFC will help produce one billion vaccine doses by the end of 2022
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
The trial will be conducted across 10 sites in India
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Findings likely to generate hypotheses about potential new uses of drugs
Subscribe To Our Newsletter & Stay Updated
